One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

NCT01844232 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Spasticity

Interventions

DRUG: arbaclofen

Sponsor

RVL Pharmaceuticals, Inc.

Collaborators

[object Object]